Terms: = Bone cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
17 results:
1. Comparison of Baseline
Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y; Rodriguez-Romanos R; Villavicencio A; Osca-Gelis G; González-Bártulos M; Llopis F; Clapes V; Oriol A; Sureda A; Escoda L; Sarrà J; Garzó A; Lloveras N; Díez I; Granada I; Gallardo D
Front Immunol; 2023; 14():1158105. PubMed ID: 37122695
[TBL] [Abstract] [Full Text] [Related]
3. Resistance to immune checkpoint inhibitors in advanced lung cancer: clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of pd-1, CTLA-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract] [Full Text] [Related]
6. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate clinical outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract] [Full Text] [Related]
7. Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.
Trentini F; Mazzaschi G; Milanese G; Pavone C; Madeddu D; Gnetti L; Frati C; Lorusso B; Lagrasta CAM; Minari R; Ampollini L; Ledda RE; Silva M; Sverzellati N; Quaini F; Roti G; Tiseo M
Tumori; 2022 Feb; 108(1):86-92. PubMed ID: 33730957
[TBL] [Abstract] [Full Text] [Related]
8. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract] [Full Text] [Related]
9. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract] [Full Text] [Related]
10. Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer.
Bocchialini G; Lagrasta C; Madeddu D; Mazzaschi G; Marturano D; Sogni F; Silini EM; Gnetti L; Becchi G; Rusca M; Carbognani P; Ventura L; Braggio C; Tiseo M; Quaini F; Ampollini L
Eur J Cardiothorac Surg; 2020 Sep; 58(3):619-628. PubMed ID: 32267920
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome after progressing to frontline and second-line Anti-pd-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract] [Full Text] [Related]
12. Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer.
Armani G; Madeddu D; Mazzaschi G; Bocchialini G; Sogni F; Frati C; Lorusso B; Falco A; Lagrasta CA; Cavalli S; Mangiaracina C; Vilella R; Becchi G; Gnetti L; Corradini E; Quaini E; Urbanek K; Goldoni M; Carbognani P; Ampollini L; Quaini F
Eur J Cardiothorac Surg; 2018 Jun; 53(6):1205-1213. PubMed ID: 29346540
[TBL] [Abstract] [Full Text] [Related]
13. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract] [Full Text] [Related]
14. Low pd-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
15. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract] [Full Text] [Related]
16. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
[TBL] [Abstract] [Full Text] [Related]
17. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract] [Full Text] [Related]